New drug cocktail shows promise in shrinking lung tumors before surgery

NCT ID NCT07538193

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for people with a specific type of advanced lung cancer (stage III-N2b non-small cell lung cancer). The goal is to see if this treatment can completely eliminate the tumor before surgery. About 28 participants will receive three cycles of the drug combo, then undergo surgery. The main measure of success is how many patients have no cancer cells left in their removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iparomlimab and tuvonralimab (a dual antibody targeting PD-1 and CTLA-4) plus platinum-based chemotherapy
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors before surgery, potentially improving outcomes for people with advanced lung cancer.
What could go wrong
This is a small, early-phase study with only 28 participants, so results may not apply to everyone. The treatment can cause immune-related side effects, and it's not yet known if it will improve long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tangdu Hospitial

    Xi'an, Shannxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.